| Item Type | Name |
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Drug Therapy
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Chemotherapy, Adjuvant
|
|
Academic Article
|
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Update on biochemical modulation of chemotherapeutic agents.
|
|
Academic Article
|
Adjuvant therapy of colon cancer.
|
|
Academic Article
|
Adjuvant therapy for colorectal cancer.
|
|
Academic Article
|
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
|
|
Academic Article
|
Prospects for fertility after cancer chemotherapy.
|
|
Academic Article
|
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.
|
|
Academic Article
|
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
|
|
Academic Article
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
|
Academic Article
|
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
|
|
Academic Article
|
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.
|
|
Academic Article
|
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
|
|
Academic Article
|
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
|
|
Academic Article
|
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
|
|
Academic Article
|
Construct validity of medicare chemotherapy claims: the case of 5FU.
|
|
Academic Article
|
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
|
|
Academic Article
|
High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
|
|
Academic Article
|
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
|
|
Academic Article
|
Laboratory and clinical studies of biochemical modulation by hydroxyurea.
|
|
Academic Article
|
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
|
|
Academic Article
|
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
|
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
|
|
Academic Article
|
Oral fluoropyrimidine treatment of colorectal cancer.
|
|
Academic Article
|
Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B.
|
|
Academic Article
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
|
Academic Article
|
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
|
|
Academic Article
|
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
|
|
Academic Article
|
Cetuximab in the treatment of colorectal cancer.
|
|
Academic Article
|
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
|
|
Academic Article
|
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
|
|
Academic Article
|
Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B.
|
|
Academic Article
|
First-line treatment options for patients with metastatic colorectal cancer.
|
|
Academic Article
|
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
|
|
Academic Article
|
Nonmalignant complications of therapy for Hodgkin's disease.
|
|
Academic Article
|
Male fertility following cancer chemotherapy.
|
|
Academic Article
|
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
|
|
Academic Article
|
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
|
|
Academic Article
|
Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience.
|
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous intravenous infusion chemotherapy: psychosocial aspects.
|
|
Academic Article
|
Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing.
|
|
Academic Article
|
Clinical trials in the era of personalized oncology.
|
|
Academic Article
|
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
|
|
Academic Article
|
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
|
|
Academic Article
|
Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial.
|
|
Academic Article
|
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
|
|
Academic Article
|
Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma.
|
|
Academic Article
|
Molecular markers to individualize adjuvant therapy for colon cancer.
|
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
|
|
Academic Article
|
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.
|
|
Academic Article
|
GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy.
|
|
Academic Article
|
Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer.
|
|
Academic Article
|
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
|
|
Academic Article
|
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
|
|
Academic Article
|
Cytarabine-cis-platin interactions in patients with advanced cancer.
|
|
Academic Article
|
Gonadal dysfunction in patients receiving chemotherapy for cancer.
|
|
Academic Article
|
Renal and metabolic toxicities of cancer chemotherapy.
|
|
Academic Article
|
Sequential therapy with dacarbazine and carmustine: a phase I study.
|
|
Academic Article
|
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.
|
|
Academic Article
|
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
|
|
Academic Article
|
Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer.
|
|
Academic Article
|
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
|
|
Academic Article
|
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
|
|
Academic Article
|
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
|
|
Academic Article
|
Ovarian function following radiation and chemotherapy for cancer.
|
|
Academic Article
|
Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer.
|
|
Academic Article
|
Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease.
|
|
Academic Article
|
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
|
|
Academic Article
|
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
|
|
Academic Article
|
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
|
|
Academic Article
|
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
|
|
Academic Article
|
The oral fluoropyrimidines in cancer chemotherapy.
|
|
Academic Article
|
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
|
|
Academic Article
|
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
|
|
Academic Article
|
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
|
|
Academic Article
|
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
|
|
Academic Article
|
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
|
|
Academic Article
|
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
|
|
Academic Article
|
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
|
|
Academic Article
|
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
|
|
Academic Article
|
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer.
|
|
Academic Article
|
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.
|
|
Academic Article
|
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
|
|
Academic Article
|
Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
|
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
|
Academic Article
|
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
|
|
Academic Article
|
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.
|
|
Academic Article
|
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement.
|
|
Academic Article
|
Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
|
|
Academic Article
|
A New IDEA in Adjuvant Chemotherapy for Colon Cancer.
|
|
Academic Article
|
American Society of Clinical Oncology 2013 top five list in oncology.
|
|
Academic Article
|
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
|
|
Academic Article
|
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer.
|
|
Academic Article
|
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
|
|
Grant
|
CALGB STUDIES OF BREAST CANCER IN THE ELDERLY
|
|
Academic Article
|
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.
|
|
Academic Article
|
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
|
Academic Article
|
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
|